Inmune Accounts Payable Trend from 2010 to 2022

INMB
 Stock
  

USD 9.30  0.86  8.46%   

Inmune Bio Accounts Payable is increasing over the years with slightly volatile fluctuation. Ongoing Accounts Payable is projected to grow to about 4.1 M this year. From 2010 to 2022 Inmune Bio Accounts Payable quarterly data regression line had arithmetic mean of 988,465 and slope of  271,169. Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).
  
Check Inmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inmune main balance sheet or income statement drivers, such as Gross Profit of 150.8 K, Operating Expenses of 31.6 M or Revenues of 150.8 K, as well as many exotic indicators such as Long Term Debt to Equity of 0.16, Receivables Turnover of 0.0592 or Accounts Payable Turnover of 0.0728. Inmune financial statements analysis is a perfect complement when working with Inmune Bio Valuation or Volatility modules. It can also supplement Inmune Bio's financial leverage analysis and stock options assessment as well as various Inmune Bio Technical models . Please see the analysis of Inmune Bio Correlation against competitors.

Inmune Accounts Payable Breakdown

Showing smoothed Accounts Payable of Inmune Bio with missing and latest data points interpolated. An accounting item on the balance sheet that represents Inmune Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inmune Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. Inmune Bio's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inmune Bio's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Increasing
Slightly volatile
   Accounts Payable   
Share
       Timeline  

Inmune Accounts Payable Regression Statistics

Arithmetic Mean 988,465
Geometric Mean 496,014
Coefficient Of Variation 139.34
Mean Deviation 1,002,063
Median 220,810
Standard Deviation 1,377,352
Range 3,893,216
R-Value 0.77
R-Squared 0.59
Significance 0.00223
Slope 271,169

Inmune Accounts Payable History

2017309.7 K
2018823.8 K
2019692.1 K
20201.6 M
20213.8 M
20224.1 M

Other Fundumenentals of Inmune Bio

Inmune Bio Accounts Payable component correlations

About Inmune Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inmune Bio income statement, its balance sheet, and the statement of cash flows. Inmune Bio investors use historical funamental indicators, such as Inmune Bio's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Inmune Bio investors may use each financial statement separately, they are all related. The changes in Inmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inmune Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inmune Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Accounts Payable3.8 M4.1 M
Accounts Payable Turnover 0.07  0.07 
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Inmune Bio Investors Sentiment

The influence of Inmune Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Inmune Bio's public news can be used to forecast risks associated with investment in Inmune. The trend in average sentiment can be used to explain how an investor holding Inmune can time the market purely based on public headlines and social activities around Inmune Bio. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Inmune Bio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Inmune Bio's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Inmune Bio's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Inmune Bio.

Inmune Bio Implied Volatility

    
  135.64  
Inmune Bio's implied volatility exposes the market's sentiment of Inmune Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inmune Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inmune Bio stock will not fluctuate a lot when Inmune Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inmune Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inmune Bio's short interest history, or implied volatility extrapolated from Inmune Bio options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inmune Bio Correlation against competitors. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
182.3 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.